RA Capital Management LXEO Position
Exited4-Fund ConvergenceRA Capital Management exited their position in Lexeo Therapeutics, Inc. (LXEO) in Q2 2025, after holding the stock for 5 quarters.
The position was first reported in Q2 2024 and has been tracked across 5 quarterly 13F filings.
LXEO is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout in 261 days (Dec 31, 2026), making the timing of RA Capital's position particularly relevant.
Short interest stands at 17.3% of float with 14.4 days to cover, indicating significant bearish positioning against the stock.
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Full company profile →Short Interest
17.3%
14.4 days to cover
RA Capital Management LXEO Position History
Frequently Asked Questions
Does RA Capital Management own LXEO?
No. RA Capital Management exited their position in Lexeo Therapeutics, Inc. (LXEO) in Q2 2025. They previously held the stock for 5 quarters.
How many hedge funds own LXEO?
4 specialist biotech hedge funds currently hold LXEO, including Eventide Asset Management, Avoro Capital Advisors, OrbiMed Advisors and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy LXEO?
RA Capital Management's position in LXEO was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's LXEO position increasing or decreasing?
RA Capital Management completely exited their LXEO position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
LXEOCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →